Pivotal bioVenture Partners Boosts Stake in Vaxcyte

Investment firm increases position in biotech company by 5.2% in Q3

Mar. 14, 2026 at 9:06am

Got story updates? Submit your updates here. ›

Pivotal bioVenture Partners Investment Advisor LLC, an institutional investor, grew its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 5.2% in the third quarter of 2026, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The firm now owns 1,372,425 shares of the biotech company's stock, making it Vaxcyte's largest institutional shareholder with a 1.05% ownership stake worth $49.4 million.

Why it matters

Vaxcyte is a clinical-stage biotech company focused on developing a new generation of preventive vaccines to combat serious bacterial diseases. The increase in Pivotal bioVenture Partners' stake suggests the investment firm sees significant potential in Vaxcyte's pipeline and future growth prospects.

The details

According to the 13F filing, Pivotal bioVenture Partners acquired an additional 67,300 shares of Vaxcyte during the third quarter, bringing its total position to 1,372,425 shares. This represents approximately 28.6% of the firm's total portfolio, making Vaxcyte its largest holding.

  • Pivotal bioVenture Partners increased its Vaxcyte stake in the third quarter of 2026.

The players

Pivotal bioVenture Partners Investment Advisor LLC

An institutional investment firm that owns a significant stake in Vaxcyte, Inc.

Vaxcyte, Inc.

A clinical-stage biotechnology company focused on developing a new generation of preventive vaccines to combat serious bacterial diseases.

Got photos? Submit your photos here. ›

The takeaway

Pivotal bioVenture Partners' increased investment in Vaxcyte suggests the firm sees strong potential in the biotech company's vaccine pipeline and future growth prospects, underscoring the market's optimism around Vaxcyte's innovative approach to addressing unmet medical needs in serious bacterial diseases.